NASDAQ:UNCY Unicycive Therapeutics (UNCY) Stock Price, News & Analysis $0.44 -0.04 (-8.66%) (As of 12:45 PM ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends About Unicycive Therapeutics Stock (NASDAQ:UNCY) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Unicycive Therapeutics alerts:Sign Up Key Stats Today's Range$0.42▼$0.4850-Day Range$0.35▼$0.5952-Week Range$0.20▼$1.82Volume1.72 million shsAverage Volume1.22 million shsMarket Capitalization$41.21 millionP/E RatioN/ADividend YieldN/APrice Target$5.13Consensus RatingBuy Company OverviewUnicycive Therapeutics, Inc., a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI 494, which is in Phase 1 clinical trials for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Altos, California.Read More… Is Your 401(k) Safe? The Real Risk No One Sees Coming (Ad)Every day you wait, your savings are at greater risk. The government isn't slowing down, inflation isn't stopping, and the digital dollar is coming. You can protect yourself—but only if you act now. Don't wake up too late. Get your Digital Dollar Protection today and secure your retirement before the window closes.Click Here For Your Free Guide Unicycive Therapeutics Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks64th Percentile Overall ScoreUNCY MarketRank™: Unicycive Therapeutics scored higher than 64% of companies evaluated by MarketBeat, and ranked 426th out of 975 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.6 / 5Analyst RatingBuy Consensus RatingUnicycive Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.20, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageUnicycive Therapeutics has only been the subject of 2 research reports in the past 90 days.Read more about Unicycive Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Unicycive Therapeutics are expected to grow in the coming year, from ($0.26) to ($0.07) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Unicycive Therapeutics is -0.46, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Unicycive Therapeutics is -0.46, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted1.24% of the float of Unicycive Therapeutics has been sold short.Short Interest Ratio / Days to CoverUnicycive Therapeutics has a short interest ratio ("days to cover") of 0.5, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous month Dividend0.0 / 5Dividend StrengthN/A Dividend YieldUnicycive Therapeutics does not currently pay a dividend.Dividend GrowthUnicycive Therapeutics does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted1.24% of the float of Unicycive Therapeutics has been sold short.Short Interest Ratio / Days to CoverUnicycive Therapeutics has a short interest ratio ("days to cover") of 0.5, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous month News and Social Media2.5 / 5News Sentiment0.50 News SentimentUnicycive Therapeutics has a news sentiment score of 0.50. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 10 news articles for Unicycive Therapeutics this week, compared to 1 article on an average week.Search InterestOnly 16 people have searched for UNCY on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat Follows11 people have added Unicycive Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 57% compared to the previous 30 days. Company Ownership2.5 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Unicycive Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders24.10% of the stock of Unicycive Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions40.42% of the stock of Unicycive Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Unicycive Therapeutics' insider trading history. Receive UNCY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Unicycive Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address UNCY Stock News HeadlinesUnicycive Therapeutics expects cash to fund operations into 2026November 14 at 12:45 AM | markets.businessinsider.comUnicycive Announces Third Quarter 2024 Financial Results and Provides Business UpdateNovember 13 at 7:15 AM | globenewswire.comIs Your 401(k) Safe? The Real Risk No One Sees ComingEvery day you wait, your savings are at greater risk. The government isn't slowing down, inflation isn't stopping, and the digital dollar is coming. You can protect yourself—but only if you act now. Don't wake up too late. Get your Digital Dollar Protection today and secure your retirement before the window closes.November 14, 2024 | Golden Crest (Ad)Unicycive Therapeutics announces U.S. FDA acceptane for NDA for OLCNovember 13 at 2:26 AM | markets.businessinsider.comPositive Buy Rating for Unicycive Therapeutics Driven by NDA Acceptance and Strong Market Potential for Oxylanthanum CarbonateNovember 13 at 2:26 AM | markets.businessinsider.comUnicycive: FDA to Review Lead Drug Candidate for HyperphosphatemiaNovember 11 at 9:51 AM | marketwatch.comUnicycive Says FDA Accepts NDA For Oxylanthanum Carbonate To Treat Patients With CKD On DialysisNovember 11 at 9:51 AM | markets.businessinsider.comUnicycive Therapeutics Announces U.S. FDA Acceptance of the New Drug Application (NDA) for Oxylanthanum Carbonate (OLC) for the Treatment of Hyperphosphatemia in Patients with Chronic Kidney Disease on DialysisNovember 11 at 7:00 AM | globenewswire.comSee More Headlines UNCY Stock Analysis - Frequently Asked Questions How have UNCY shares performed this year? Unicycive Therapeutics' stock was trading at $0.8677 at the start of the year. Since then, UNCY shares have decreased by 44.9% and is now trading at $0.4781. View the best growth stocks for 2024 here. How were Unicycive Therapeutics' earnings last quarter? Unicycive Therapeutics, Inc. (NASDAQ:UNCY) released its quarterly earnings data on Thursday, November, 11th. The company reported ($0.37) EPS for the quarter, missing the consensus estimate of ($0.11) by $0.26. When did Unicycive Therapeutics IPO? Unicycive Therapeutics (UNCY) raised $25 million in an initial public offering on Tuesday, July 13th 2021. The company issued 4,600,000 shares at a price of $5.00-$6.00 per share. Roth Capital Partners served as the underwriter for the IPO and EF Hutton (formerly Kingswood Capital Markets) was co-manager. Who are Unicycive Therapeutics' major shareholders? Unicycive Therapeutics' top institutional investors include Great Point Partners LLC (9.07%), Acuta Capital Partners LLC (2.10%) and Bleakley Financial Group LLC (0.08%). View institutional ownership trends. How do I buy shares of Unicycive Therapeutics? Shares of UNCY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Unicycive Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Unicycive Therapeutics investors own include Sangamo Therapeutics (SGMO), Meta Platforms (META), ADC Therapeutics (ADCT), Citius Pharmaceuticals (CTXR), DocGo (DCGO), NVIDIA (NVDA) and Adicet Bio (ACET). Company Calendar Last Earnings11/11/2021Today11/14/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:UNCY CUSIPN/A CIK1766140 Webwww.unicycive.com Phone650-351-4495FaxN/AEmployees9Year FoundedN/APrice Target and Rating Average Stock Price Target$5.13 High Stock Price Target$9.00 Low Stock Price Target$2.50 Potential Upside/Downside+1,054.3%Consensus RatingBuy Rating Score (0-4)3.20 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($1.05) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-30,540,000.00 Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on Assets-34.98% Debt Debt-to-Equity RatioN/A Current Ratio3.37 Quick Ratio3.37 Sales & Book Value Annual Sales$680,000.00 Price / Sales61.61 Cash FlowN/A Price / Cash FlowN/A Book Value($0.11) per share Price / Book-4.04Miscellaneous Outstanding Shares94,360,000Free Float71,616,000Market Cap$41.90 million OptionableNot Optionable Beta2.29 20 High-Yield Dividend Stocks that Could Ruin Your RetirementAlmost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.Get This Free Report This page (NASDAQ:UNCY) was last updated on 11/14/2024 by MarketBeat.com Staff From Our PartnersIs Your 401(k) Safe? The Real Risk No One Sees ComingEvery day you wait, your savings are at greater risk. The government isn't slowing down, inflation isn't stopp...Golden Crest | SponsoredBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredBlackrock’s Sending THIS Crypto Higher on PurposeIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredCentral Bank Abandons USDStartling new evidence shows the U.S. Central Bank is abandoning the currency we’ve relied on for centuries – ...True Gold Republic | SponsoredTrump’s Back, but DC’s Coming for Your Money!Trump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | SponsoredTrump’s IRS Hands Massive ‘Victory Gift’ To 401K OwnersTrump quietly left open an "off the books" wealth-protection loophole hidden in the 6,871 pages of the IRS Tax...Colonial Metals | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored[625,000% Gain] – Are You Ready for the Next Altcoin Boom?All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you k...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Unicycive Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Unicycive Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.